Last reviewed · How we verify
NCT07339462: MhINT Recovery
Feasibility and Acceptability of an Intervention to Support People With Severe Mental Illness in South Africa
NA trial testing Multilevel psychosocial support for people living with severe mental illness and their caregivers in Mental Disorders, Severe in 86 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | University of KwaZulu |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 86 |
| Start date | 1 August 2025 |
| Primary completion | 1 June 2026 |
| Estimated completion | 31 August 2026 |
| Sites | 1 location across South Africa |
Drugs / interventions tested
- Multilevel psychosocial support for people living with severe mental illness and their caregivers
Conditions studied
- Mental Disorders, Severe — all drugs for Mental Disorders, Severe →
Sponsor
University of KwaZulu
Who can join
18 and older, any sex, with Mental Disorders, Severe. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Despite commendable progress in developing mental health systems in low-and-middle income countries, critical gaps remain, particularly the development of community-based systems of support for people living with severe mental illness (SMIs). This application will pilot a co-developed health system strengthening intervention programme in a South African district in order to determine its feasibility, appropriateness and limited efficacy in reducing readmission following discharge from acute psychiatric hospitalization. By generating preliminary data on the real-world implementation of a co-developed programme in low-resource contexts in South Africa, this application seeks to build on an existing foundation of research partnerships and local government collaboration to develop a transitional support intervention that could yield significant and tangible impacts on people living with SMIs in low-resource communities.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07339462
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mental Disorders, Severe
Currently open trials in the same condition.
- NCT04881084 — Exploring Empathy and Compassion Using Digital Narratives · NA · recruiting
- NCT05834309 — Exercise Effects on Health Status in Patients With Severe Mental Illness · NA · recruiting
Other University of KwaZulu trials
Trials by the same sponsor.
- NCT06516549 — Evaluation of Skipping Rope and Informational Pamphlet Among Adolescents in South Africa · NA · recruiting
- NCT06429475 — Anti-Inflammatory Reliever South Africa · Phase 3 · recruiting
- NCT06248190 — ENHANCE-EvideNce Led Co-created HeAlth Systems interventioNs for MLTCs CarE · NA · completed
- NCT05061407 — An African, Multi-centre Evaluation of Patient Care and Clinical Outcomes for Paediatric Patients Undergoing Surgery · completed
- NCT04746547 — Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07339462 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of KwaZulu
- Last refreshed: 14 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07339462.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing